Transferrin‐Targeted Nanoarchitectonics with Efficient Metastasis Inhibition Enabling Tumor T 1 ‐T 2 Dual‐Mode Magnetic Resonance Contrast Enhancement
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500690 ↗At a glance
Journal article in Advanced Healthcare Materials, 2025. Written by Yinuo Yuan and 11 co-authors. Institution: Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China. Major MEDLINE topics: Contrast Media, Magnetic Resonance Imaging, Transferrin, Neoplasms. Cited 3 times so far (Crossref); 32 references. Funded by: Taishan Scholar Foundation of Shandong Province, Collaborative Academic Innovation Project of Shandong Cancer Hospital.
Abstract (original language)
The development of T 1 ‐T 2 dual‐mode contrast agents is expected to improve cancer diagnostic capabilities in response to the limitation of traditional single‐mode magnetic resonance imaging (MRI) contrast agents. In this study, a pH‐responsive dual‐mode MRI nanoprobe, Fe 3 O 4 @MnS‐transferrin (FMT), is prepared with the objective of augmenting tumor visualization and chemodynamic therapy (CDT). FMT achieved precise tumor targeting by binding to transferrin receptors on cancer cells via the transferrin molecules on their surface. FMT underwent pH‐responsive decomposition in the acidic tumor microenvironment, releasing Fe 3 O 4 and Mn 2+ . This decomposition increased the spatial separation between Fe 3 O 4 and Mn 2+ , attenuating the mutual magnetic shielding effect and activating dual‐mode MRI function. Moreover, FMT released Mn 2+ and hydrogen sulfide (H 2 S). Mn 2+ triggered a Fenton‐like reaction, generating reactive oxygen species that induced cytotoxicity through CDT. Concurrently, H 2 S inhibited catalase activity, providing additional substrates for the Fenton‐like reaction, thereby amplifying CDT in a cascading manner. This synergistic mechanism amplified the cytotoxicity of CDT, enhancing the efficacy of tumor treatment and metastasis inhibition. Therefore, FMT demonstrated significant promise for enhancing both the precision of tumor imaging and the efficacy of treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
- Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China.
- Clinical Medicine, First Clinical Medical College of Zhengzhou University, Zhengzhou, 450001, China.
- Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, 100853, China.
ORCID profiles: Xiao Sun
Funding
- Taishan Scholar Foundation of Shandong Province
- Collaborative Academic Innovation Project of Shandong Cancer Hospital
Cite
APA
Yuan, Y., Tian, L., Liu, X., Guo, K., Ren, K., Yan, L., Mu, M., Liu, S., Teng, F., Liu, C., Liang, P., & Sun, X. (2025). Transferrin‐Targeted Nanoarchitectonics with Efficient Metastasis Inhibition Enabling Tumor T 1 ‐T 2 Dual‐Mode Magnetic Resonance Contrast Enhancement. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500690
Vancouver
Yuan Y, Tian L, Liu X, Guo K, Ren K, Yan L, et al. Transferrin‐Targeted Nanoarchitectonics with Efficient Metastasis Inhibition Enabling Tumor T 1 ‐T 2 Dual‐Mode Magnetic Resonance Contrast Enhancement. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500690
BibTeX
@article{Yuan2025,
author = {Yuan, Yinuo and Tian, Liya and Liu, Xinyu and Guo, Kai and Ren, Ke and Yan, Lei and Mu, Mengyao and Liu, Shangui and Teng, Feifei and Liu, Cun and Liang, Ping and Sun, Xiao},
title = {Transferrin‐Targeted Nanoarchitectonics with Efficient Metastasis Inhibition Enabling Tumor T 1 ‐T 2 Dual‐Mode Magnetic Resonance Contrast Enhancement},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500690}
}
EUVIMED